AA
FDMT icon

ALPS Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

ALPS Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32,811
Closed -$106K – 1038
2025
Q1 		$106K Sell
32,811
-4,568
-12% -$21.5K ﹤0.01% 978
2024
Q4 		$208K Sell
37,379
-1,964
-5% -$15.4K ﹤0.01% 971
2024
Q3 		$425K Sell
39,343
-1,012
-3% -$16.8K ﹤0.01% 630
2024
Q2 		$847K Buy
40,355
+5,246
+15% +$132K 0.01% 501
2024
Q1 		$1.12M Buy
35,109
+6,077
+21% +$155K 0.01% 448
2023
Q4 		$588K Buy
+29,032
New +$382K ﹤0.01% 579
2022
Q4 		– Sell
-17,663
Closed -$142K – 1049
2022
Q3 		$142K Sell
17,663
-1,492
-8% -$13.5K ﹤0.01% 1021
2022
Q2 		$134K Buy
+19,155
New +$186K ﹤0.01% 1018

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ALPS Advisors's FDMT Position: Q2 2025 in Review

ALPS Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q2 2025, closing a stake of 32,811 shares — an estimated $106K sold.

ALPS Advisors first reported a position in FDMT in Q2 2022 and held it in 8 quarters. The position peaked at $1.12M in Q1 2024. 120 funds tracked by Wall St. Rank hold FDMT as of Q2 2025.

  • ALPS Advisors reported no remaining 4D Molecular Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 32,811 4D Molecular Therapeutics shares in Q2 2025, an estimated $106K.
  • ALPS Advisors first reported a position in 4D Molecular Therapeutics in Q2 2022 and held it in 8 quarters.
  • ALPS Advisors's 4D Molecular Therapeutics position peaked at $1.12M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.